

MMA Center for Quality Improvement / Maine Chapter, AAP

Block 4: Treatment – Beginning to Explore the Many Facets of Treatment





A better tomorrow starts today.







TreatMe Learning Collaborative Partners







A better tomorrow starts today.







Important Webinar Notes

- You are in listen-only mode, today's session is being recorded and will be sent out in a follow up email.
- Raffle winner will be announced at the end of today's webinar.
- Please use the Q&A function (top of the screen) to ask questions or make comments. The chat function is disabled.
- Should you want to ask a question using your audio, please use the "Raise Your Hand" function on your top left zoom dashboard. Webinar host will "promote" you to a panelist so you can ask your question.
- Video screen size and location are adjustable.
- When this zoom call ends, the follow-up survey will automatically open in a new window. A link to your CME/MOC and Certificate of Attendance will be available upon completion of the survey. More about CME/MOC and Certificate of attendance will be discussed on the next slide.
- If you have any questions, please email: admin@treatme.info





CME/MOC Information

- CME/MOC and Certificate of Attendance are available for the attendees of this webinar.
- If you are attending by sharing the computer screen of a registered participant, please type your name and email address into the Q&A box. We will send you a link for the survey after this session.
- When this webinar ends, your survey will automatically open in a new window. A link to your CME/MOC and the Certificate of Attendance will be available for download upon completion of the survey.
- If you are unable to complete the survey at this time you will also be receiving an email with today's recording and the survey link in 1 business day.
- <u>The survey must be completed within two week to receive CME/MOC and/or Certificate</u> of Attendance.





Funding Provided By:

The TREAT ME Learning Collaborative. Made possible by the generous support of the Maine Health Access Foundation's *Systems Improvement and Innovation Responsive Grants* (SIIRG) program, and the Office of Child and Family Services.





Disclosure

Today's speakers have no relevant financial relationships with the manufacturer(s) of any commercial product(s) and/or provider of commercial services discussed in this CME activity





Presenters



Kevin M. Simon, MD Chief Behavioral Health Officer, *City of Boston* Child, Adolescent, and Adult Psychiatrist & Addiction Medicine Specialist, *Boston Children's Hospital*

Dr. Kevin Simon was appointed the first Chief Behavioral Health Officer for the City of Boston. In addition, he is an Attending Psychiatrist at Boston Children's Hospital, an Instructor in Psychiatry at Harvard Medical School, a Commonwealth Fund Fellow in Health Policy at Harvard University, and a Medical Director of Wayside Youth & Family Support Network. Dr. Simon practices as a Pediatric & Adult Psychiatrist and Addiction Medicine specialist through the Adolescent Substance use & Addiction Program at Boston Children's Hospital.





Adolescent OUD/SUD & Co-Occurring Mental Illness

March 16, 2023

Kevin M. Simon, M.D.

Child, Adolescent, and Adult Psychiatrist & Addiction Medicine Specialist

Chief Behavioral Health Officer, City of Boston

Instructor of Psychiatry, Harvard Medical School

Attending Psychiatrist, Boston Children's Hospital

Boston Children's Hospital Adolescent Substance Use & Addiction Program





Opioid Response Network

Working with communities.

- The SAMHSA-funded Opioid Response Network (ORN) assists states, organizations and individuals by providing the resources and technical assistance they need locally to address the opioid crisis and stimulant use.
- Technical assistance is available to support the evidence-based prevention, treatment and recovery of opioid use disorders and stimulant use disorders.

Funding for this initiative was made possible (in part) by grant no. 1H79TI083343 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.



Working with communities.

- The Opioid Response Network (ORN) provides local, experienced consultants in prevention, treatment, and recovery to communities and organizations to help address this opioid crisis and stimulant use.
- ORN accepts requests for education and training.
- Each state/territory has a designated team led by a regional Technology Transfer Specialist (TTS), who is an expert in implementing evidence-based practices.




Contact the Opioid Response Network

To ask questions or submit a request for technical assistance:

- Visit www.OpioidResponseNetwork.org
- Email orn@aaap.org
- Call 401-270-5900









Boston Children's Hospital

National Institute of Drug Abuse





Learning Objectives

- Describe the adolescent brain development, the chronic disease model of mental illness & SUD, and the impact of substances on the brain.
- Explain the laws and best practices regarding incorporating confidential conversations and confidential documentation of adolescent substance abuse and the boundaries of confidentiality in medical care.
- Review evidence of pharmacologic treatment of adolescent substance use disorder.





Adolescent Neurodevelopment



Adolescence




Figure 1: Commonly used age definitions of specific terms of relevance for adolescence that span or overlap with the developmental periods of childhood, adolescence, and adulthood

Colour shading highlights variation in the lower and upper age limits of the term. Stripes denote a term that sits within more than one developmental stage.






Where the world comes for answers

Addiction Begins in Adolescence

ADDICTION IS A DEVELOPMENTAL DISEASE starts in adolescence and childhood




NIAAA National Epidemiologic Survey on Alcohol and Related Conditions, 2003.








Brain Maturation







Rational Thinking Gap







© Children's Hospital Boston 2021. All Rights Reserved. For permissions contact ASAP project manager at asap@childrens.harvard.edu

18



Neurobiology & Chronic Disease Model of SUD

Neurobiology of Addiction

The NEW ENGLAND JOURNAL of MEDICINE

REVIEW ARTICLE

Dan L. Longo, M.D., Editor

Neurobiologic Advances from the Brain Disease Model of Addiction

Nora D. Volkow, M.D., George F. Koob, Ph.D., and A. Thomas McLellan, Ph.D.

HIS ARTICLE REVIEWS SCIENTIFIC ADVANCES IN THE PREVENTION AND treatment of substance-use disorder and related developments in public policy. In the past two decades, research has increasingly supported the view that addiction is a disease of the brain. Although the brain disease model of addiction has vielded effective preventive measures, treatment interventions, and public health policies to address substance-use disorders, the underlying concept of substance abuse as a brain disease continues to be questioned, perhaps because Bethesda, MD 20892, or at nvolkow@ the aberrant, impulsive, and compulsive behaviors that are characteristic of addiction have not been clearly tied to neurobiology. Here we review recent advances in N Engl J Med 2016;374:363-71. the neurobiology of addiction to clarify the link between addiction and brain func-

tion and to broaden the understanding of addiction as a brain disease. We review findings on the desensitization of reward circuits, which dampens the ability to feel pleasure and the motivation to pursue everyday activities; the increasing strength of conditioned responses and stress reactivity, which results in increased cravings for alcohol and other drugs and negative emotions when these cravings are not sated; and the weakening of the brain regions involved in executive functions such as decision making, inhibitory control, and self-regulation that leads to repeated relapse. We also review the ways in which social environments, developmental stages, and genetics are intimately linked to and influence vulnerability and recovery. We conclude that neuroscience continues to support the brain disease model of addiction. Neuroscience research in this area not only offers new opportunities for the prevention and treatment of substance addictions and related behavioral addictions (e.g., to food, sex, and gambling) but may also improve our understanding of the fundamental biologic processes involved in voluntary behavioral control

In the United States, 8 to 10% of people 12 years of age or older, or 20 to 22 million people, are addicted to alcohol or other drugs.1 The abuse of tobacco, alcohol, and illicit drugs in the United States exacts more than \$700 billion annually in costs related to crime, lost work productivity, and health care.24 After centuries of efforts to reduce addiction and its related costs by punishing addictive behaviors failed to produce adequate results, recent basic and clinical research has provided clear evidence that addiction might be better considered and treated as an acquired disease of the brain (see Box 1 for definitions of substance-use disorder and addiction). Research guided by the brain disease model of addiction has led to the development of more effective methods of prevention and treatment and to more informed public health policies. Notable examples include the Mental Health Parity and Addiction Equity Act of 2008, which requires medical insurance plans to provide the same coverage for substance-use disorders and other mental illnesses that is provided for other illnesses,5 and the proposed bipartisan Senate legislation that

N ENGLIMED 374'4 NEIM.ORG IANUARY 28, 2016

The New England Journal of Medicine

Downloaded from neim.org at Boston Children's Hospital Medical Library on October 3, 2021. For personal use only. No other uses without nermission Copyright @ 2016 Massachusetts Medical Society. All rights reserved




© Children's Hospital Boston 2021. All Rights Reserved. For permissions contact ASAP project manager at asap@childrens.harvard.edu




DOI: 10.1056/NEJMra1511480 Copyright © 2016 Massachusetts Medical Society.

363



Behavioral Response of Addiction







Mental Health



A Public Health Crisis: Pediatric Mental Health

Child & Adolescent Psychiatric Disorders





Experienced a psychiatric disorder within the past year

Experience a psychiatric disorder within their lifetime



Of psychiatric disorders **begin** by age 14 and three-quarters by age 25



Of children with psychiatric disorders **receive treatment**



Average delay between symptom onset & treatment initiation






© Children's Hospital Boston 2021. All Rights Reserved. For permissions contact ASAP project manager at asap@childrens.harvard.edu

Where the world comes for answers

Mental Health Trends in Teens

High School Student Trends




Where the world comes for answers

Tenfold Increase in Boarded Days



Boston Children's ED Visits/Month







Substance Use




© Children's Hospital Boston 2021. All Rights Reserved. For permissions contact ASAP project manager at asap@childrens.harvard.edu

Where the world comes for answers

A Public Health Crisis: Adolescent Substance Use???


U.S. Students Reporting Any Past-Year Illicit Drug Use*







Course of Substance Use by Age



Source: Dennis (2002) and 1998 NHSDA.






© Children's Hospital Boston 2021. All Rights Reserved. For permissions contact ASAP project manager at asap@childrens.harvard.edu

Where the world comes for answers

Younger Start, Longer Use



29

Maine Adolescent Substance Use

- ME teens are 47.44% more likely to have used substances last month than average teens.
- ♦ 12% 12-17yo reported substance use last month
 - 90% 12-17yo reported marijuana use last month
- ♦ 18% 12-17yo reported marijuana use last year
- ♦ 10% 12-17yo reported ETOH use last month
- ♦ 1.1% 12-17yo reported cocaine use last year
- ♦ 0.6% 12-17yo reported heroin use last year







© Children's Hospital Boston 2021. All Rights Reserved. For permissions contact ASAP project manager at asap@childrens.harvard.edu

Co-occurring

Disorders

Adolescents with SUD...

- ♦ Are largely undiagnosed
- Are distributed across diverse health & social service systems
- Have histories of child abuse, neglect, and sexual abuse;
- Have high co-morbidity with psychiatric conditions;





© Children's Hospital Boston 2021. All Rights Reserved. For permissions contact ASAP project manager at asap@childrens.harvard.edu

Simon et. al, NEJM 2022

Co-occurring Disorders Stats

- The majority of adolescents with SUDs will have other mental illnesses.
- 37-80% of adolescents with SUDs have at least one mental illness.
- Most common is ADHD (30-70%)
- The relationship b/w psych sxs & substance use is bidirectional
- ♦ 40-90% have experienced trauma

Simon et. al, NEJM 2022





Substance Use Disorder – Criteria



The 5 C's of Addiction

- 1. <u>Craving</u> and preoccupation with non-therapeutic use
- 2. <u>Compulsive</u> opioid use
- 3. Loss of <u>Control</u> over opioid use
- 4. <u>Continued</u> use of opioids despite harm
- 5. <u>Chronic maladaptive</u> behaviors associated with use





DSM-5 Substance (Opioid) Use Disorder Criteria

"A problematic pattern of substance use leading to clinically significant impairment or distress, as manifested by at least <u>2</u> of the following, occurring within a <u>12 month period</u>..."





DSM-5 Substance (Opioid) Use Disorder Criteria

♦ Impaired Control

- 1. Use in larger amount or longer than intended
- 2. Desire or unsuccessful effort to cut down
- 3. Great deal of time using or recovering
- 4. Craving or strong urge to use*
- ♦ Social Impairment
 - 5. Role obligation failure
 - 6. Continued use despite social / interpersonal problems
 - 7. Sacrificing activities to use or because of use
- ♦ <u>Risky Use</u>
 - 8. Use in situations where it is hazardous
 - 9. Continued use despite knowledge of having physical or psychological problem caused or exacerbated by use



Meuroadapative / Physiologic

Tolera https://www.commonscience.com/commonscience/com

Where the world comes for answers ithdrawal

Oral Case Discussions



Consent



Confidentiality Laws & Rules

- Substance use disorder treatment program records
 - 42 C.F.R. Part 2
- HIPAA Privacy Rule
 - 45 C.F.R. Parts 160 and 164
- Maine health care information confidentiality law
 - 22 M.R.S. § 1711-C
- Records of licensed mental health agencies or facilities
 - 34-B M.R.S. § 1207
 - Rights of Recipients of Mental Health Services
 - Right of Recipients of Mental Health Services Who Are Children in Need of Treatment







- AMA Code of Medical Ethics Opinion 8.08, Informed Consent
 - "Patient's right of self-decision[:]" "The physician's obligation is to present the medical facts accurately to the patient . . . and to make recommendations for management in accordance with good medical practice."
- ♦ Key elements
 - Nature & purpose of the treatment
 - Risk & consequences involved in the treatment
 - Alternative courses of treatment, including the consequences of no treatment
 - An opportunity for the patient to ask questions





Where the world comes for answers

Sensitive Type of Treatment

- All minors (under 18yo) may give consent to certain sensitive types of treatment where an obligation of parental consent may be an obstacle to treatment and therefore, may not be in the best interest of the minor.
 - Family planning services 22 M.R.S.A. sec. 1908
 - Treatment of venereal disease or drug or alcohol abuse by a physician – 32 M.R.S.A. secs. 2595 & 3292
 - Treatment of drug or alcohol abuse or for emotional or psychological problems – 22 M.R.S.A. sec. 1502
 - Certain services provided by alcohol & drug counselors, social workers, or psychologists 32 M.R.S.A. secs. 6221, 7004, & 3817
 - Treatment of venereal disease or drug or alcohol abuse in the hospital setting, but parental consent is required if hospitalization continues for more than 16 hours – 22 M.R.S.A. sec. 1823.





State Policies on Substance Use During Pregnancy

		STATE POLICIE	S ON SUBSTA	NCE USE DU	JRING PREGN	ANCY	
	SUBSTANCE USE DURING PREGNANCY CONSIDERED:		WHEN DRUG USE DIAGNOSED OR SUSPECTED, STATE REQUIRES:		DRUG TREATMENT FOR PREGNANT INDIVIDUALS		
STATE	Child Abuse	Grounds for Civil Commitment	Reporting	Testing	Targeted Program Created	Pregnant People Given Priority Access in General Programs	Pregnant People Protected from Discrimination in Publicly Funded Programs
Alabama	X.			2 		×	×
Alaska	1		×				
Arizona	×		×			×	
Arkansas	×		×		X	×	
California			x		×		
Colorado	×				Xq		
Connecticut					×		
Delaware						×	
District of Columbia	×		×	1		×	
Florida	×				X		X
Georgia						×	
Illinois	×		×		Xŝ	×	×
Indiana	X+			×	×		
Iowa	×		×	×		X	×
Kansas						×	×
Kentucky	X		x	х	×	×	×
Louisiana	×		×	x			
Maine	~		×			x	
Maryland			~		×	~	
Massachusetts	1		x				
Michigan	1995 - 1995 - 1995 - 1995 - 1995 - 1995 - 1995 - 1995 - 1995 - 1995 - 1995 - 1995 - 1995 - 1995 - 1995 - 1995 -		x				
Minnesota	x	X	×	x	X		
Missouri	X ^Ω	~	~	~	<u>م</u>	X	×
					5	~.	~
Montana			×				
Nebraska							
Nevada	×		×				
New York					×		
North Carolina					×		
North Dakota	×		×	х			
Ohio	X		×		×	x	×
Oklahoma			×			×	×
Oregon					Ę		
Pennsylvania	1		×	f (×		
Rhode Island	×		×	×			
South Carolina	×-			0	×		
South Dakota	×	X	×	×			
Tennessee					XS	×	×
Texas	×						
Utah	×		×			×	
Virginia	×		×		XS		
Washington	×				X4		
West Virginia	1.000			P	******	Xo	
Wisconsin	×	x	×		×	X ^µ	
TOTAL	23+DC	3	25+DC	8	19	17+DC	10
	20.00		20.00				





Oral Case Discussions



Evidence-based behavioral interventions for adolescent SUD

- Motivation Interviewing / Motivational Enhancement Therapy
- Cognitive Behavioral Therapy
- Family-based Therapy
- Multisystemic Therapy
- Adolescent Community Reinforcement Approach (A-CRA)





Purpose of Family Involvement

- Learn about the child from family members
- Mutual education and redefinitions
- Define substance use in the family context
- Establish/re-establish parental influence

To decrease family resistance to treatment





Parental Guidance



The C's of Parental Guidance

- Cash (Debit & Credit cards)
- Cars (Privileges)
- Cellphone (Privileges)
- Chores (Incentives)
- Communication (Open Frame)
- Companions (Friends & Peers)
- Computer (Online & Social Media)
- Curfew (Incentive & Trust)





Pharmacologic Treatment Evidence



Alcohol

SUD	Meds	Study	Participants	Methods	Results
AUD	Naltrexone	Miranda '13	22 non-tx seeking adolescents who consumed ETOH ≥ 2x in the 30 days pre- recruitment. Age range: 15 – 19 Gender: 12 F Race: 72% White, 18% AAAPI	Tx: Naltrexone 50mg Control: Placebo	 Naltrexone: ↓ Drinking & heavy drinking (p < 0.003) ↓ Craving in the lab & natural environment (p < 0.04) ↓ Subjective responses to alcohol consumption (p < 0.01)
AUD	Naltrexone	O'Malley '15	128 non-tx seeking emerging adults who reported ≥4 heavy drinking days (≥4 drinks W & ≥5 drinks M) in the 4 wks before study enrollment. Age range: 18 – 25 Gender: 68.8% M Race: 77% W, 8% AA	Tx: Naltrexone 50mg Control: Placebo All received psychosocial interventions	Naltrexone: No grp diff b/w heavy drinking days & % days abstinent ↓ # of drinks per drinking day & % of drinking days w/ est BAC ≥ 0.08





Tobacco

SUD	Meds	Study	Participants	Methods	Results
TUD	NRT	Hanson '03	100 tx-seeking youth who smoked ≥ 10 CPD for ≥ 6 mo Age range: 13 – 19 Gender: 43% male Race: 87% white	Tx: Nicotine patch (21, 14, 7mg/d) Control: placebo patch All received CBT & CM	NRT: ↓ craving scores and overall withdrawal symptoms Safe and effective as monotherapy or when combined with counseling, not as effective as in adult who smoke
TUD	NRT	Moolchan '05	120 tx-seeking adolescents who smoked ≥ 10 CPD for ≥ 6 mo Age range: 13 – 17 Gender: 70% F Race: 73% W	Tx: active patch (21, 14, 7mg/d) & placebo gum or active gum (2 or 4mg) & placebo patch Control: placebo patch All received CBT	Confirmed prolonged abstinence rates of active-patch group (18%) vs. placebo (2.5%). Abstinence rates for the active gum condition (6.5%) did not differ by condition
TUD	NRT	Roddy '06	98 tx-seeking youth who smoked daily Age range: 11 – 21 Gender: 42% male Race: not reported	Tx: Nicotine patch (15, 10, 5mg/d) Control: placebo patch All received wkly individual & grp counseling	NRT: At 4 wks, 5% patch grp was abstinent vs. 2% placebo At 13 wks, 0% patch & placebo were abstinent
	le le	Hospital		Rights Reserved. For permissions contact	ASAP project manager at 50

Where the world comes for answers

Tobacco

SUD	Meds	Study	Participants	Methods	Results
TUD	NRT	Rubinstein '08	40 adolescent who smoked ≥5 CPD for ≥ 6 mo Age range: 15 – 18 Gender: 54% female Race: "less than half being white"	Tx: Nicotine nasal spray (1 mg total) for 6 wks Control: none All participants received eight sessions of American Lung Association's Not On Tobacco curriculum.	No grp diff in cessation rates ($p = 0.16$), number of CPD ($p = 0.22$), or cotinine levels at 12 wks ($p = 0.16$).
TUD	NRT	Scherphorf '14	257 tx-seeking Dutch adolescents who smoked ≥ 7 CPD. Age range: 12 - 18 Gender: 53% female Race: not reported	Tx: 21, 14, 7 mg nicotine patch based on number of CPD at time of enrollment Control: placebo patch	 NRT: Doubled abstinence rates after 2 weeks (OR = 2.02, 95% CI = 1.11-3.69), but no diff at end of tx. End-of-tx abstinence rates ↑ in high-compliant (OR = 1.09, 95% CI = 1.01-1.17) and not in low compliant participants.





Tobacco

SUD	Meds	Study	Participants	Methods	Results
TUD	Bupropion	Killen '04	211 tx-seeking adolescents who (1) smoked ≥10 CPD, (2) smoked for ≥ 6 mo, (3) had 1+ failed quits. Age: 15 – 18 Gender: 69% M Race: 50% W, 12% Hispanic, 7% Asian	Tx: nicotine patch & bupropion SR (150 mg QD) Control: nicotine patch & placebo All participants received wkly grp skills training.	No diff b/w abstinence rates at 10 or 26 wks (1) patch & bupropion 23% and 8%, (2) patch & placebo 28% and 7%
TUD	Bupropion	Muramoto '04	312 tx-seeking adolescents who smoke ≥6 CPD, exhaled CO level of ≥ 10 ppm, 2 quit attempts. Age: 14 – 17 Gender: 54% male Race: 74% W, 15% Hispanic	Tx: Bupropion SR 150mg QD or 300mg QD Control: placebo All participants received wkly brief counseling.	 6 wks: Cotinine-confirmed 7- day point prevalence abstinence rates: placebo, 5.6%; 150 mg, 10.7%; and 300 mg, 14.5% (<i>p</i> = 0.03, 300 mg vs placebo). 26 wks: Confirmed point prevalence abstinence rates: placebo, 10.3%; 150 mg, 3.1%; and 300 mg, 13.9% (<i>p</i> = 0.049).





Tobacco

SUD	Meds	Study	Participants	Methods	Results
TUD	Bupropion	Gray '11	134 tx-seeking adolescents who smoke ≥ 5 CPD w/ baseline urine cot > 100 ng/mL. Age: 12 – 21 Gender: 58% male Race: 89% W	Tx: (1) bupropion SR + CM (2) bupropion SR alone Control: (3) placebo + CM (4) Placebo alone	Combined bupropion SR + CM yielded significantly superior abstinence rates during active treatment when compared with placebo and no CM treatment: bupropion SR and CM 27%, bupropion SR without CM 8%, placebo and CM 10%, and placebo and non-CM 9%.
TUD	Varenicline	Gray '19	29 tx-seeking adolescents who smoke ≥ 5 CPD Age range: 12 – 21 Gender: 58% M Race: not reported	Interventions: Varenicline (≤2mg) vs. bupropion sustained release (150–300 mg) Control: none	 Varenicline (relative to bupropion): ↓ cigarettes smoked per day from 14.1 ± 6.3 to 0.9 ± 2.1 and those receiving bupropion XL reduced from 15.8 ± 4.4 to 3.1 ± 4.0. Compared with placebo, varenicline was well tolerated but did not support improved end-of-treatment abstinence for adolescent smokers.





Cannabis

SUD	Meds	Study	Participants	Methods	Results
CUD	NAC	Gray '12	 116 treatment-seeking adolescents who met criteria for DSM-IV cannabis dependence Age range: 13 – 21 Gender: 72.4% male Race: 83% white 	Tx: NAC 1200 mg QD Control: Placebo BID All received CM and wkly brief individual smoking cessation counseling.	 NAC: 2x the odds of submitting negative urine cannabinoid tests during treatment (OR 2.4, 1.1–5.2, p = 0.029), with detectable differences within the first week of treatment. Time to first negative urine cannabinoid test and end-of- treatment abstinence favored NAC but non-significant.
TUD	Topiramate	Miranda '19	66 tx-seeking adolescents using cannabis ~ 2x wkly in 30 days before study participation & experienced ≥ 1 sxs of cannabis abuse or dependence (DSM-IV). Age range: 15 – 24 Gender: 54% female Race: 50% white	 Tx: Topiramate 25mg, titrated by 25 – 50mg over 4 wks to 200 mg/day for the last 2 wks of study. Control: Placebo All participants received biweekly MET for treating cannabis use among adolescents. 	Topiramate: No improvement in abstinence rates. ↓ the # of grams of marijuana smoked per use day





Opioids

SUD	Meds	Study	Participants	Methods	Results
OUD	Buprenorphine	Marsch '05	36 self-referred treatment- seeking adolescents who met DSM-IV criteria for opioid dependence. Age range: 13 – 18 Gender: 39% male Race: 97% white	 Tx: Outpt detox w/bup (≤8 mg) + placebo patch vs. clonidine (≤3 mg) patch + placebo tablets Control: none All received counseling 	 ↑ Retention in bup grp (72%) vs. clonidine (39%) (p < 0.05) ↑ Percentage of opioid negative urine tests (64% vs. 32%, p = 0.01).
OUD	Buprenorphine/N aloxone	Woody '08	66 tx-seeking adolescents using cannabis ~ 2x wkly in 30 days before study participation & experienced ≥ 1 sxs of cannabis abuse or dependence (DSM-IV). Age range: 15 – 24 Gender: 54% female Race: 50% white	Tx: 14-day outpt detox (≤14 mg of bup) vs. 12-week bup/nal (≤24 mg) Control: none All received wkly individual & grp counseling	 Compared to detox grp, participants in the 12-wk bup/nal grp showed the following: ↓ Opioid-positive urine tests at wk 4 (26% vs. 61%) & 8 (23% vs. 54%), but not at wk 12 (43% vs. 51%). ↓ reported opioid use before wk6 (p < .001) ↓ reported injections before wk 6 (p = .01) ↓ cocaine & marijuana use
OUD	Buprenorphine	Marsch '16	53 adolescents who met DSM- IV opioid dependence criteria Age range: 16 – 24 Gender: 58% male Race: 70% white	Tx: 28- day or 56-day buprenorphine/nal oxone detoxification and followed over a 63-day study period.	Participants who received a 56-day bup taper were retained in tx 11 days longer on avg than participants who received a 28-day bup taper. Participants who received a 56-day bup taper had a ↑ percentage of opioid-negative scheduled urine tests compared with participants who received a 28-day bup taper (35 vs. 17%).

Hospital

Methamphetamine

SUD	Meds	Study	Participants	Methods	Results
OUD	Bupropion	Heinzerling '13	19 youth with DSM-IV methamphetamine abuse or dependence and low frequency of methamphetamine use (use on ≤18/30 days). Age range: 14 – 21 Mean age: 17.6 ± 1.4 Gender: 47% male Race: 70% white	Intervention: Bupropion SR 150 mg twice daily Control: placebo All participants receive group drug counseling	Adolescents receiving bupropion and females provided significantly fewer methamphetamine-free urine tests compared to participants receiving a placebo (<i>p</i> = 0.043) and males (<i>p</i> = 0.005), respectively, compared to placebo.







- Adolescent substance use is a serious problem with potentially life-threatening consequences
- Pediatric healthcare providers can have a significant impact on this problem by:
 - Screening their patients for substance use
 - Using caution in prescribing
 - Counseling patients and parents about prescription drug misuse
 - Supporting medication for patients with severe substance use disorders





Acknowledgments

Adolescent Substance use and Addiction Program (ASAP)

Physicians

- Diana Deister, MD, MS
- John Fantegrossi, NP (Nurse Practitioner)
- Sharon Levy, MD, MPH
- Miriam Schizer, MD, MPH (Medical Director)
- Patricia Schram, MD
- Kevin M. Simon, MD
- Jennifer Ross, MD

Addiction Medicine Fellows

- Emily Nields, DO (Family Medicine)
- Modar Sukkarieh, MD (Developmental Pediatrician)
- Omar Shah, MD (Child & Adolescent Psychiatrist)
- Samantha Taylor (Child & Adolescent Psychiatrist)

Clinical Social Workers

- Amy McCarthy Baluch, LICSW
- Leslie Green, MSW, LICSW
- Shannon Mountain-Ray, MSW, LICSW
- Jessica Peters, MA, MSA, LICSW
- Jesse Schram, LICSW
- Emmett Walsh, LICSW

Research Staff

- Melissa Brogna, MSW
- Benjamin Ertman, BS
- Elyse Neubauer, MA
- Sarah Simon
- Laura Blakemore

Teaching Collaborators

- Pamela Burke, PhD, RN, FNP, PNP, FSAHM, FAAN
- Linda Malone, DNP, RN, CPNP
- Sarah Pitts, MD
- Marianne Pugatch, MSW, LICSW
- Jennifer Putney, PhD, LICSW

Research Collaborators

- Co-principal investigators: Sharon Levy, MD, MPH, Kevin M. Simon, MD, Elissa Weitzman, ScD, Msc
- Elizabeth Harstad, MD, MPH
- Lauren Wisk, PhD

Research Project Management

- Julie Lunstead, MPH, Program Manager
- Rachele Cox, MPH, Clinical Research Specialist I
- Alyssa Fuller, MPH, Clinical Research Specialist III
- Alexandra Marin, PhD, Data Manager

PCSS MAT Training

Providers' Clinical Support System for POUD





Prize Winner!!!!! *Breakfast at a Bakery*

Choice of:



or



To be eligible you must complete the asynchronous session evaluation for the block and be present for the live webinar.





Next Steps

- 1. Reminder you will receive a survey for your CME/MOC and Certificate of Attendance following this webinar via email.
- 2. We are also asking that you complete a survey for the ORN to give them feedback.
- 3. Go to treatme.info
- 4. Click on Block 5 Now Live in the top right-hand corner to access the asynchronous materials and videos.

admin@treatme.info





Next Live Webinar

Date

April 20th, 2023 12pm-1pm



Topic Co-Occurring Medical Illness

Speaker Emily Nields, DO





Save the Date!

Half-Day In-Person Session

June 22nd, 2023 8:00am-1pm

Topics

Evidence-Based Practices for Adolescence and Substance Use Disorders

Getting Started with the Patient

Acute Toxidromes

Speakers

Jesse Hinckley, MD, PhD

Elizabeth Samuels, Md, MPH, MHS

Jason Reynolds, MD, PhD

Amy Mayhew, Md, MPH

Dylan McKenney, MD







Thank you!

Please fill out our brief survey

https://tinyurl.com/Mar-Simon



Contact Information









A better tomorrow starts today.

Marshall McLaughlin

Project Manager mmclaughlin@mainemed.com

Jeff Aalberg, MD, MS

Family Medicine Physician, Medical Director jeffreya@day-one.org



